Aerie Pharmaceuticals, Inc. (AERI) Upgraded by BidaskClub to Sell

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Monday, July 24th.

Several other equities research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price objective on the stock in a research report on Monday, July 24th. Cowen and Company set a $100.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 26th. Stifel Nicolaus reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, May 26th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $62.00 price objective (up from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $66.08.

Aerie Pharmaceuticals (NASDAQ AERI) opened at 53.05 on Monday. Aerie Pharmaceuticals has a 52 week low of $18.52 and a 52 week high of $59.50. The firm’s 50-day moving average is $54.36 and its 200-day moving average is $48.37. The firm’s market cap is $1.93 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, equities analysts anticipate that Aerie Pharmaceuticals will post ($2.56) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Aerie Pharmaceuticals, Inc. (AERI) Upgraded by BidaskClub to Sell” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/19/aerie-pharmaceuticals-inc-aeri-raised-to-sell-at-bidaskclub-updated-updated-updated.html.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.36% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Aerie Pharmaceuticals by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after buying an additional 49,473 shares during the last quarter. State Street Corp raised its position in shares of Aerie Pharmaceuticals by 36.9% in the fourth quarter. State Street Corp now owns 820,644 shares of the company’s stock valued at $31,059,000 after buying an additional 221,146 shares during the last quarter. BlackRock Inc. raised its position in shares of Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in shares of Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after buying an additional 3,739 shares during the last quarter. Finally, Turner Investments LLC bought a new position in shares of Aerie Pharmaceuticals during the first quarter valued at $227,000. Institutional investors and hedge funds own 87.74% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit